An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Dexcom recalled certain glucose monitoring receivers that may fail to make an alert sound when blood sugar is dangerously low ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

The latest international Eli Lilly and Co news and views from Reuters - one of the world's largest news agencies ...

Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...